Asacol Magasýruþolin tafla 800 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

asacol magasýruþolin tafla 800 mg

tillotts pharma ab - mesalazinum inn - magasýruþolin tafla - 800 mg

Asacol Magasýruþolin tafla 400 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

asacol magasýruþolin tafla 400 mg

tillotts pharma ab - mesalazinum inn - magasýruþolin tafla - 400 mg

Asacol Endaþarmsstíll 500 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

asacol endaþarmsstíll 500 mg

tillotts pharma ab - mesalazinum inn - endaþarmsstíll - 500 mg

Asacol (Mesalazine ESPL) Tafla með breyttan losunarhraða 1600 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

asacol (mesalazine espl) tafla með breyttan losunarhraða 1600 mg

tillotts pharma ab - mesalazinum inn - tafla með breyttan losunarhraða - 1600 mg

Asacol (Mesalazine ESPL) Endaþarmsstíll 1 g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

asacol (mesalazine espl) endaþarmsstíll 1 g

tillotts pharma ab - mesalazinum inn - endaþarmsstíll - 1 g

Asacol Endaþarmsdreifa 10 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

asacol endaþarmsdreifa 10 mg/ml

tillotts pharma ab - mesalazinum inn - endaþarmsdreifa - 10 mg/ml

Cortiment Forðatafla 9 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

cortiment forðatafla 9 mg

ferring lægemidler a/s - budesonidum inn - forðatafla - 9 mg

Dasatinib Krka Filmuhúðuð tafla 70 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

dasatinib krka filmuhúðuð tafla 70 mg

krka d.d. novo mesto* - dasatinibum inn - filmuhúðuð tafla - 70 mg

Dasatinib Accord Evrópusambandið - íslenska - EMA (European Medicines Agency)

dasatinib accord

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - Æxlishemjandi lyf - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Dasatinib Accordpharma Evrópusambandið - íslenska - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - Æxlishemjandi lyf - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.